---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-22-000575"
form_type: "8-K"
ticker: "CMMB"
cik: "0001534248"
company_name: "Chemomab Therapeutics Ltd."
filed_at: "2022-02-11T23:59:59+00:00"
generated_at: "2026-06-27T08:44:45.591733+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Chemomab shareholders approve CEO Dale Pfost as Chairman of the Board

## Summary
- Special meeting on Feb 10, 2022; 89,749,560 shares represented (~39.35% of outstanding).
- Shareholders voted to approve CEO Dr. Dale Pfost as Chairman of the Board.
- Vote results: 84,227,920 FOR, 5,510,320 AGAINST, 11,320 ABSTAIN.
- Requisite majority under Israeli Companies Law satisfied; non-controlling shareholder votes also approved.

## SEC filing metadata
- accession: 0001178913-22-000575
- form_type: 8-K
- ticker: CMMB
- cik: 0001534248
- company_name: Chemomab Therapeutics Ltd.
- filed_at: 2022-02-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534248/000117891322000575/0001178913-22-000575-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534248/000117891322000575/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-22-000575
- JSON: https://secwatch.observer/filing/0001178913-22-000575.json
- Plain text: https://secwatch.observer/filing/0001178913-22-000575.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.